Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

578

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: RTV
DRUG: ATV
DRUG: DRV
DRUG: COBI
DRUG: ATV/co
DRUG: DRV/co
DRUG: FTC/TDF
DRUG: ABC/3TC
DRUG: B/F/TAF

Sponsor

Gilead Sciences